AGENERASE
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 27m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGENERASE is an oral capsule small-molecule drug approved by GSK in 1999. The specific indication and mechanism of action are not publicly detailed in this dataset. This product is approaching loss of exclusivity, indicating a mature lifecycle stage.
LOE Approaching
This product is in late-stage lifecycle with limited remaining exclusivity, suggesting a small-to-declining brand team focused on lifecycle management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for AGENERASE roles. Working on this product offers limited growth trajectory but provides exposure to lifecycle management, generic transition strategy, and mature-product commercial operations—valuable skills for career development in pharma.
Brand ManagerCommercial Operations Manager
Worked on AGENERASE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.